Studies indicate that CDK4/6 inhibitors induce G1‐phase arrest in HNSCC cells, followed by synchronized S‐phase entry upon withdrawal, thereby amplifying the cytotoxic effects of chemotherapy (e.g., cisplatin, 5‐FU) or radiotherapy.[34] Previous studies have investigated administering targeted inhibitors or chemoradiotherapy in sequence with ICIs.[22, 35] Only a 23.1% objective response rate was observed in a clinical trial evaluating the safety and efficacy of concurrent ribociclib (CDK4/6i) and spartalizumab (anti‐PD‐1) for HNSCC. The gene discussed is CDK4; the disease is head and neck squamous cell carcinoma.